133 related articles for article (PubMed ID: 38513975)
1. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
Bortz C; Armistead I; Bonaguidi A; Coyle DT
J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
[TBL] [Abstract][Full Text] [Related]
2. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
3. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
4. COVID-19-related flexibility in methadone take-home doses associated with decreased attrition: Report from an opioid treatment program in central Pennsylvania.
Kawasaki SS; Zimmerman R; Shen C; Zgierska AE
J Subst Use Addict Treat; 2023 Dec; 155():209164. PubMed ID: 37730014
[TBL] [Abstract][Full Text] [Related]
5. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
6. Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis.
Hoffman KA; Foot C; Levander XA; Cook R; Terashima JP; McIlveen JW; Korthuis PT; McCarty D
J Subst Abuse Treat; 2022 Oct; 141():108801. PubMed ID: 35589443
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and current clinical practices of opioid treatment programs in the United States.
Jones CM; Byrd DJ; Clarke TJ; Campbell TB; Ohuoha C; McCance-Katz EF
Drug Alcohol Depend; 2019 Dec; 205():107616. PubMed ID: 31678836
[TBL] [Abstract][Full Text] [Related]
8. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
[TBL] [Abstract][Full Text] [Related]
9. Acceptability, feasibility, and outcomes of a clinical pilot program for video observation of methadone take-home dosing during the COVID-19 pandemic.
Hallgren KA; Darnton J; Soth S; Blalock KL; Michaels A; Grekin P; Saxon AJ; Woolworth S; Tsui JI
J Subst Abuse Treat; 2022 Dec; 143():108896. PubMed ID: 36215911
[TBL] [Abstract][Full Text] [Related]
10. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
[TBL] [Abstract][Full Text] [Related]
11. Impacts of the COVID-19 pandemic on enrollment in medications for opioid use disorder (MOUD) in Vancouver, Canada: An interrupted time series analysis.
Eugenia Socias M; Choi JC; Fairbairn N; Johnson C; Wilson D; Debeck K; Brar R; Hayashi K
Int J Drug Policy; 2023 Aug; 118():104075. PubMed ID: 37271070
[TBL] [Abstract][Full Text] [Related]
12. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
13. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
[TBL] [Abstract][Full Text] [Related]
14. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
15. A trial of implementation facilitation to increase timely admission to methadone treatment.
Gryczynski J; Mitchell SG; Whitter M; Fuller D; Mitchell MM; Edelman EJ; Schwartz RP
J Subst Use Addict Treat; 2024 Jul; 162():209375. PubMed ID: 38642889
[TBL] [Abstract][Full Text] [Related]
16. Introduction of Medicare coverage in opioid treatment programs: Findings from the first three years.
Abraham AJ; Harris SJ; Yarbrough CR
J Subst Use Addict Treat; 2024 Mar; 158():209247. PubMed ID: 38072386
[TBL] [Abstract][Full Text] [Related]
17. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
18. Opioid use and COVID-19: a secondary analysis of the impact of relaxation of methadone take-home dosing guidelines on use of illicit opioids.
Panwala V; Thorn E; Amiri S; Socias ME; Lutz R; Amram O
Am J Drug Alcohol Abuse; 2023 Sep; 49(5):597-605. PubMed ID: 37433122
[No Abstract] [Full Text] [Related]
19. Evaluating interventions to facilitate opioid agonist treatment access among people who inject drugs in Toronto, Ontario during COVID-19 pandemic restrictions.
Bouck Z; Scheim AI; Gomes T; Ling V; Caudarella A; Werb D
Int J Drug Policy; 2022 Jun; 104():103680. PubMed ID: 35447476
[TBL] [Abstract][Full Text] [Related]
20. Methadone dosing at New York State opioid treatment programs following initial revisions to federal regulations.
Jordan AE; Bachhuber MA; Tuazon E; Jimenez C; Lincourt P; Hussain S; Rubinfeld J; Cunningham CO
Drug Alcohol Depend; 2024 May; 258():111283. PubMed ID: 38581920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]